A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized Anti-HER-2/neu responses in women with early breast cancer

Journal of Immunotherapy

Volumn 35, Issue 1, 2012, Pages 54-65

  Koski, Gary K ^a,b   Koldovsky, Ursula ^b   Xu, Shuwen ^b   Mick, Rosemarie ^b   Sharma, Anupama ^b   Fitzpatrick, Elizabeth ^b   Weinstein, Susan ^b   Nisenbaum, Harvey ^b   Levine, Bruce L ^b   Fox, Kevin ^b   Zhang, Paul ^b   Czerniecki, Brian J ^a,b  

^a KENT STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

breast cancer; dendritic cell; HER 2 neu; vaccine

Indexed keywords

DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; HLA A2 ANTIGEN; LIPOPOLYSACCHARIDE;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INGUINAL LYMPH NODE; INTRADUCTAL CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; TH1 CELL; TUMOR CELL;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CARCINOMA, DUCTAL; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; NEOPLASM STAGING; RECEPTOR, ERBB-2; TH1 CELLS;

EID: 84155163266     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318235f512     Document Type: Article

References (44)

1. Medzhitov R, Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev. 2000;173:89-97.
2. Rock FL, Hardiman G, Timans JC, et al. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA. 1998;95:588-593.
3. Cheong C, Matos I, Choi JH, et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell. 2010;143:416-429.
4. Zinkernagel RM. Restriction by H-2 gene complex of transfer of cell mediated immunity to Listeria monocytogenes. Nature. 1974;251:230-234.
5. Linsley PS, Clark EA, Ledbotter JA. T cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/B1. PNAS. 1990;87:5031-5037.
6. Kalinski P, Hilkens CM, Wierenga EA, et al. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today. 1999;20:561-567.
7. Kapsenberg ML, Hilkens CM, Wierenga EA, et al. The paradigm of type 1 and type 2 antigen-presenting cells: implications for atopic allergy. Clin Exp Allergy. 1999; 29(suppl 2):33-36.
8. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235-238.
9. Chen Y, Langrish CL, McKenzie B, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest. 2006;116: 1317-1326.
10. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875-1886.
11. Napolitani G, Rinaldi A, Bertoni F, et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005;6:769-776.
12. Chow JC, Young DW, Golenbock DT, et al. Toll-like receptor-4 mediates lipopolysaccharide-induced signal trans-duction. J Biol Chem. 1999;274:10689-10692.
13. Fisk B, Blevins TL, Wharton JT, et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995;181:2109-2117.
14. Kono K, Rongcun Y, Charo J, et al. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer. 1998;78: 202-208.
15. Disis ML, Grabstein KH, Sleath PR, et al. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res. 1999;5:1289-1297.
16. Czerniecki BJ, Koski GK, Koldovsky U, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007;67:1842-1852.
17. Czerniecki BJ, Carter C, Rivoltini L, et al. Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J Immunol. 1997;159:3823-3837.
18. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001;93: 243-251.
19. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002;195:1279-1288.
20. Berger TG, Haendle I, Schrama D, et al. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells. Int J Cancer. 2004;111:229-237.
21. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-3142.
22. Sallusto F, Lenig D, Mackay CR, et al. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. 1998;187:875-883.
23. Andrew DP, Chang MS, McNinch J, et al. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol. 1998;161: 5027-5038.
24. Ruppert J, Schutt C, Ostermeier D, et al. Down-regulation and release of CD14 on human monocytes by IL-4 depends on the presence of serum or GM-CSF. Adv Exp Med Biol. 1993; 329:281-286.
25. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83-93.
26. Kiertscher SM, Roth MD. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol. 1996; 59:208-218.
27. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus inter-leukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
28. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA. 1996;93:2588-2592.
29. Steinman RM, Inaba K. Myeloid dendritic cells. Leukoc Biol. 1999;66:205-208.
30. Lyakh LA, Koski GK, Young HA, et al. Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14(+) monocytes cultured under serum-free conditions. Blood. 2002;99:600-608.
31. Koski GK, Lyakh LA, Rice NR. Rapid lipopolysaccharide-induced differentiation of CD14(+) monocytes into CD83(+) dendritic cells is modulated under serum-free conditions by exogenously added IFN-gamma and endogenously produced IL-10. Eur J Immunol. 2001;31:3773-3781.
32. Lyakh LA, Koski GK, Telford W, et al. Bacterial lipopoly-saccharide, TNF-alpha, and calcium ionophore under serum-free conditions promote rapid dendritic cell-like differentiation in CD14+ monocytes through distinct pathways that activate NK-kappa B. J Immunol. 2000;165:3647-3655.
33. Bedrosian I, Mick R, Xu S. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol. 2003;21:3825-3835.
34. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260:547-549.
35. Barth RJ Jr, Mule JJ, Spiess PJ, et al. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med. 1991;173:647-645.
36. Filatenkov AA, Jacovetty EL, Fischer UB, et al. CD4 T cell-dependent conditioning of dendritic cells to produce IL-12 results in CD8-mediated graft rejection and avoidance of tolerance. J Immunol. 2005;174:6909-6917.
37. Curtsinger JM, Lins DC, Johnson CM, et al. Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis. J Immunol. 2005;175:4392-4399.
38. Valenzuela JO, Hammerbeck CD, Mescher MF. Cutting edge: Bcl-3 up-regulation by signal 3 cytokine (IL-12) prolongs survival of antigen-activated CD8 T cells. J Immunol. 2005; 174:600-604.
39. Xu S, Koski GK, Faries M, et al. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol. 2003;171:2251-2261.
40. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 1998;58:4902-4908.
41. Dhodapkar MV, Young JW, Chapman PB, et al. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Clin Cancer Res. 2000;6:4831-4838.
42. Santini SM, Lapenta C, Logozzi M, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med. 2000;191:1777-1788.
43. Vidalain PO, Azocar O, Yagita H, et al. Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. J Immunol. 2001;167:3765-3772.
44. Manna PP, Mohanakumar T. Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro. J Leukoc Biol. 2002;72:312-320.